Company profile
INHIBIKASE THERAPEUTICS, INC.
NASDAQ:IKTBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IKT-001PRO | phase3 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05623774 | phase1 | completed | 2022-12-16 | 2024-06-30 | Inhibikase Therapeutics | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg |
| NCT06643143 | phase2 | withdrawn | 2025-06-30 | 2027-06-30 | Inhibikase Therapeutics | A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) |
| NCT07365332 | phase3 | recruiting | 2026-04-23 | 2029-06-01 | Inhibikase Therapeutics | An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
| NCT07632898 | phase3 | not_yet_recruiting | 2026-10-23 | 2030-06-30 | Inhibikase Therapeutics | Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
FDA applications (0)
No records yet.